Holen Sie sich die Stockscreener-App
273.41
0.19%
0.53
Handel nachbörslich:
273.41
Schlusskurs vom Vortag:
$272.88
Offen:
$272.78
24-Stunden-Volumen:
1.01M
Relative Volume:
1.15
Marktkapitalisierung:
$13.05B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$-182.84M
KGV:
-72.71
EPS:
-3.7603
Netto-Cashflow:
$391.29M
1W Leistung:
-1.77%
1M Leistung:
-2.37%
6M Leistung:
+79.91%
1J Leistung:
+80.35%
1-Tages-Spanne:
$270.88
$282.90
1-Wochen-Bereich:
$267.27
$282.90
52-Wochen-Spanne:
$144.26
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
273.41 | 13.28B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Hochstufung | CLSA | Hold → Outperform |
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Should Automated Test Cartridge Expansion Require Action From Charles River Shares Investors? - simplywall.st
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Labs stock edges lower as investors weigh FY 2026 guidance and conference schedule - ad-hoc-news.de
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences - Yahoo! Finance Canada
Charles River Labs stock heads into the open after a 1.4% dip - ad-hoc-news.de
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Charles River Labs stock trades near TD Cowen target as Amundi trims position - ad-hoc-news.de
Charles River Labs stock heads into the open after a 0.3 percent dip - ad-hoc-news.de
Charles River Labs stock trades near TD Cowen target after recent gains - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Laboratories International (CRL) Could Be 8% Undervalued After Endosafe Automation Ramp - simplywall.st
One investor controls millions of Charles River (NYSE: CRL) shares - Stock Titan
Charles River Launches Automated Endosafe Manufacturing Suite - Contract Pharma
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite - Investing News Network
Charles River now inspects every testing cartridge, not just samples - Stock Titan
Charles River Laboratories Inte (CRL): Analyst Consensus and Growth Potential Amidst Market Volatility - DirectorsTalk Interviews
Charles River Labs stock holds steady as investors look to recent earnings - ad-hoc-news.de
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Charles River Labs stock trades near yearly high as analysts flag valuation risks - ad-hoc-news.de
Charles River Laboratories stock gains as valuation stretches above fair value estimates - ad-hoc-news.de
How Investors Are Reacting To Charles River (CRL) Deepening Its Role In Complex Vaccine Development - simplywall.st
Charles River Laboratories International Inc (CRL) Shares Surge 3.3% -- What GF Score of 70 Tells Investors - GuruFocus
LRT Capital Management, LLC's Charles River Laboratories International Inc(CRL) Holding History - GuruFocus
Is This the Right Time to Add CRL Stock to Your Portfolio? - TradingView
Charles River Labs stock holds near recent highs as earnings beat and analyst optimism support the r - ad-hoc-news.de
Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership? - simplywall.st
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River Laboratories (CRL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations - DirectorsTalk Interviews
Charles River Laboratories (CRL) Earnings History & Trends - 24/7 Wall St.
Resilient Charles River Labs stock trades close to its 52-week high as analysts see limited upside - AD HOC NEWS
Charles River (NYSE: CRL) director exercises options, sells stock at $300 - Stock Titan
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock? - Yahoo Finance
Charles River (NYSE: CRL) director plans new sale after $24.8M stock sales - Stock Titan
Charles River and Medigen partner to speed up next-generation Enterovirus vaccine - Indian Pharma Post
Is Charles River (CRL) Quietly Redefining Its Edge Through Complex Biologics and Vaccine Testing? - simplywall.st
Charles River Labs stock holds close to new 52-week high as Q2 2026 beat and guidance hike support r - ad-hoc-news.de
Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge? - Yahoo Finance
What Does Charles River Laboratories International (CRL) Gain From This Vaccine Collaboration? - simplywall.st
Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development? - Yahoo Finance
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running? - TradingView
Charles River Labs stock holds near fresh 52-week high after strong Q2 earnings - ad-hoc-news.de
Are Options Traders Betting on a Big Move in Charles River Stock? - TradingView
Charles River Gains 88.6% in a Year: What's Driving the Rally? - Yahoo Finance
Madison Asset Management LLC Invests $3.81 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs CEO Birgit Girshick Gifts 528 Shares, Retains Significant Ownership - Kalkine Media
Charles River Laboratories Director Nancy C. Andrews Reports Form 4 Filing on Stock Option Exercise and Sale - Kalkine Media
Charles River Labs CEVP Parisotto sells $599,710 in shares By Investing.com - Investing.com Australia
Charles River Laboratories International (NYSE:CRL) Director Nancy Andrews Sells 573 Shares - MarketBeat
Charles River (NYSE: CRL) CEO makes 528-share gift of common stock - Stock Titan
Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):